Description

Technical Parameters

Product Introduction

Incretin Analogs BGM0504 represents a patented molecular compound with dual therapeutic applications. Primarily prescribed for managing type 2 diabetes, it functions by regulating blood sugar levels effectively. Moreover, it serves as an anti-obesity medication, supporting sustained weight management over extended periods. This dual functionality underscores its significance in addressing two critical health concerns: diabetes control and obesity treatment. By targeting both conditions, BGM0504 not only enhances metabolic health but also supports comprehensive patient care strategies aimed at improving overall wellness and quality of life. Its innovative formulation and proven efficacy make it a valuable asset in modern medical treatments aimed at combating the challenges posed by diabetes and obesity.

R&D Development

BGM0504: A Dual Agonist in Clinical Phase Ⅱ

Molecule Design: Introducing a novel dual agonist with worldwide patent protection.

GLP-1R Agonist

● Confirmed clinical benefits include

Improved glycemic control

Reduction in body weight

Enhancement of various cardiovascular risk factors

GIPR Agonist

● Potential benefits encompass

Multiple pathways enhancing the effectiveness of GLP-1R agonists

Mitigation of emesis and alleviation of illness-related behaviors triggered by GLP-1R activatio

Certificate Display

product-1561-480

Exhibition Photos

product-1562-559

Company Profile

product-1561-649

FAQ

Q: 1.What is the difference between GIP and GLP-1?

A: GIP also promotes energy storage via direct actions on adipose tissue, and enhances bone formation via stimulation of osteoblast proliferation and inhibition of apoptosis. In contrast, GLP-1 exerts glucoregulatory actions via slowing of gastric emptying and glucose-dependent inhibition of glucagon secretion.

Q: 2.What drugs are GLP-1/GIP Agonists?

A: ●List of GLP-1 agonists
●Dulaglutide (Trulicity®).
●Exenatide (Byetta®).
●Exenatide extended-release (Bydureon®).
●Liraglutide (Victoza®).
●Lixisenatide (Adlyxin®).
●Semaglutide injection (Ozempic®).
●Semaglutide tablets (Rybelsus®).

Q: 3.How offer do you take GLP-1 agonists?

A: Your healthcare provider will tell you when and how often to take your medication (usually injections). Be sure to follow their instructions.
But, in general, the frequencies of the injections are:
●Dulaglutide: Once a week.
●Exenatide: Twice a day.
●Exenatide extended-release: Once a week.
●Liraglutide: Once a day.
●Lixisenatide: Once a day.
●Semaglutide: Once a week.
●Tirzepatide: Once a week.
Semaglutide tablets are a daily medication.
4.What foods are high in GLP-1?
Consuming foods like whole grains, nuts, eggs, and vegetables can help increase GLP-1 levels, which may aid in managing diabetes and promoting satiety.

Q: 5.Is there a GIP medication for weight loss?

A: GIP works by promoting dietary lipid storage and acts in the central nervous system to lower food intake. There is currently only 1 FDA-approved GLP-1/GIP agonist for weight loss (tirzepatide). A 72-week trial for this medication showed a significant weight loss benefit compared to placebo that was dose dependant.

Q: 6.When should I need to take a GLP-1 agonist?

A: Healthcare providers prescribe GLP-1 agonists for two conditions: Type 2 diabetes and obesity.

Hot Tags: incretin analogs bgm0504, China incretin analogs bgm0504 manufacturers, suppliers, Anti winkle Peptides Hexapeptide 9, whitening ingredient, 100403-19-8, 910463 68 2 Oral, Anti aging EUK 134 Powder, 179186-46-0